{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:09:20Z","timestamp":1784257760406,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Current pharmacovigilance (PV) methods for detection of adverse drug reactions (ADRs) fail to capture rare immune-mediated drug hypersensitivity reactions (DHRs) due to their scarcity and the lack of clear diagnostic criteria. Drug-induced serum sickness-like reactions (SSLRs) are rare type of DHRs that occur in susceptible patients 1\u20133 weeks after exposure to the culprit drug with \u00df-lactam antibiotics being the most associated drugs. The diagnosis of drug induced SSLR is difficult due to the lack of safe and reliable diagnostic tests for identifying the culprit drug. The lymphocyte toxicity assay (LTA) is an <jats:italic>in vitro<\/jats:italic> test used as a diagnostic tool for drug hypersensitivity reactions (DHRs).<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To evaluate the role of the LTA test for diagnosing and capturing SSLR due to \u00df-lactam antibiotics in a cohort of patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients were recruited from patients referred to the Drug Hypersensitivity Clinic at Clinic at London Health Science Centre with suspicion of drug allergy. Twenty patients (10 males and 10 females) were selected to be tested to confirm diagnosis. Demographic data was collected form the patents and blood samples were withdrawn from all patients and from 20 healthy controls. The LTA test was performed on all subjects and data is expressed as percentage increase in cell death compared to control (vehicle without the drug).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In the result of LTA tests performed on samples from the selected 20 patients. There was a significant (<jats:italic>p<\/jats:italic> &amp;lt; 0.05) concentration-dependent increase in cell death in cells isolated from patients as compared to cells from healthy controls when incubated with the drug in the presence of phenobarbitone-induced rat liver microsomes.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Giving its safety and good predictive value the LTA test has very strong potential to be a useful diagnostic tool for \u00df-lactam-induced SSLR. The test procedure is relatively simple and not overly costly. Further studies including other drug classes are needed to evaluate the utility of the LTA test for SSLR due to other drugs.<\/jats:p>","DOI":"10.3389\/fphar.2022.945545","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T06:55:03Z","timestamp":1661842503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of in vitro testing in pharmacovigilance for \u00df-lactam-induced serum sickness-like reaction: A pilot study"],"prefix":"10.3389","volume":"13","author":[{"given":"Abdelbaset A.","family":"Elzagallaai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awatif M.","family":"Abuzgaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca R.","family":"Del Pozzo-Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Loubani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Rieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bcp.12944","article-title":"Adverse drug event reporting systems: A systematic review","volume":"82","author":"Bailey","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1001\/jama.277.4.307","article-title":"The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group","volume":"277","author":"Bates","year":"1997","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1001\/archinte.165.13.1500","article-title":"Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions","volume":"165","author":"Benahmed","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.clinthera.2018.07.012","article-title":"Pharmacovigilance: An overview","volume":"40","author":"Beninger","year":"2018","journal-title":"Clin. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in europe: A review of recent observational studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdcr.2021.11.004","article-title":"Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine","volume":"19","author":"Chaijaras","year":"2022","journal-title":"JAAD Case Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/bcp.12474","article-title":"Adverse drug reactions - examples of detection of rare events using databases","volume":"80","author":"Chan","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e17877","DOI":"10.7759\/cureus.17877","article-title":"Serum sickness-like reactions after pneumococcal vaccination","volume":"13","author":"Chung","year":"2021","journal-title":"Cureus"},{"key":"B9","first-page":"1000279","article-title":"Severe serum sickness-like reaction: Challenges in diagnosis and management","volume":"6","author":"De Schryver","year":"2015","journal-title":"J. C Exp. Dermatol Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/pch\/pxab003","article-title":"Paediatric serum sickness-like reaction: A 10-year retrospective cohort study","volume":"26","author":"Del Pozzo-Magana","year":"2021","journal-title":"Paediatr. Child. Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13223-021-00535-4","article-title":"DRESS induced by amoxicillin-clavulanate in two pediatric patients confirmed by lymphocyte toxicity assay","volume":"17","author":"Dhir","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/cpt.677","article-title":"Adverse drug reactions in children: The double-edged sword of therapeutics","volume":"101","author":"Elzagallaai","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF03256387","article-title":"Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndrome","volume":"14","author":"Elzagallaai","year":"2010","journal-title":"Mol. Diagn. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF03256336","article-title":"In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: A systematic review","volume":"13","author":"Elzagallaai","year":"2009","journal-title":"Mol. Diagn. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/jcph.85","article-title":"The predictive value of the in vitro platelet toxicity assay (iPTA) for the diagnosis of hypersensitivity reactions to sulfonamides","volume":"53","author":"Elzagallaai","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/bcp.12505","article-title":"In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology","volume":"80","author":"Elzagallaai","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0091270010365554","article-title":"The in vitro platelet toxicity assay (iPTA): A novel approach for assessment of drug hypersensitivity syndrome","volume":"51","author":"Elzagallaai","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/01.rhu.0000262585.18582.1e","article-title":"Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia","volume":"13","author":"Finger","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/oxfordjournals.aje.a115663","article-title":"Serum sickness in children after antibiotic exposure: Estimates of occurrence and morbidity in a health maintenance organization population","volume":"132","author":"Heckbert","year":"1990","journal-title":"Am. J. Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1046\/j.1440-1754.2001.00632.x","article-title":"Serum sickness-like reaction to cefaclor","volume":"37","author":"Isaacs","year":"2001","journal-title":"J. Paediatr. Child. Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/archinte.155.18.1949","article-title":"Drug-related morbidity and mortality. A cost-of-illness model","volume":"155","author":"Johnson","year":"1995","journal-title":"Arch. Intern. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/s0022-3476(06)80187-3","article-title":"Serum sickness-like reactions to cefaclor: Role of hepatic metabolism and individual susceptibility","volume":"125","author":"Kearns","year":"1994","journal-title":"J. Pediatr. X."},{"key":"B23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0009-9236(98)90093-5","article-title":"Serum sickness-like reaction to cefaclor: Lack of in vitro cross-reactivity with loracarbef","volume":"63","author":"Kearns","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.anai.2016.05.013","article-title":"Hypersensitivity and immunologic reactions to biologics: Opportunities for the allergist","volume":"117","author":"Khan","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(00)03137-8","article-title":"Idiosyncratic drug reactions: The reactive metabolite syndromes","volume":"356","author":"Knowles","year":"2000","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJM198411293112204","article-title":"A prospective clinical and immunologic analysis of patients with serum sickness","volume":"311","author":"Lawley","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: A systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.1994.178","article-title":"Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach","volume":"56","author":"Naranjo","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/00007691-200212000-00008","article-title":"Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals","volume":"24","author":"Neuman","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"B31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0009-9120(00)00146-6","article-title":"A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes","volume":"33","author":"Neuman","year":"2000","journal-title":"Clin. Biochem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.trsl.2006.12.001","article-title":"Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides","volume":"149","author":"Neuman","year":"2007","journal-title":"Transl. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1086\/260107","article-title":"An evaluation of consumer protection legislation: The 1962 drug amendments","volume":"81","author":"Peltzman","year":"1973","journal-title":"J. Political Econ."},{"key":"B34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.mcna.2010.04.003","article-title":"Drug hypersensitivity reactions: Pathomechanism and clinical symptoms","volume":"94","author":"Pichler","year":"","journal-title":"Med. Clin. North Am."},{"key":"B35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/infdis\/158.2.474","article-title":"Serum sickness-like reactions to amoxicillin, cefaclor, cephalexin, and trimethoprim-sulfamethoxazole","volume":"158","author":"Platt","year":"1988","journal-title":"J. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/pds.2155","article-title":"Market withdrawal of new molecular entities approved in the United States from 1980 to 2009","volume":"20","author":"Qureshi","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jama.1996.03540120028017","article-title":"Cefaclor and serum sickness-like reaction","volume":"276","author":"Reynolds","year":"1996","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/ijerph19073754","article-title":"Quality of spontaneous reports of adverse drug reactions sent to a regional pharmacovigilance unit","volume":"19","author":"Salvador","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9554.1000279","article-title":"Severe serum sickness-like reaction: Challenges in diagnosis and management","volume":"6","author":"Schryver","year":"2015","journal-title":"J. Clin. Exp. Dermatology Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/bmj.302.6784.1051","article-title":"Allergy to penicillin: Fable or fact?","volume":"302","author":"Surtees","year":"1991","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/pr.113.007450","article-title":"Idiosyncratic adverse drug reactions: Current concepts","volume":"65","author":"Uetrecht","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7326\/0003-4819-67-3-596","article-title":"Serum sickness. Evidence in man of antigen-antibody complexes and free light chains in the circulation during the acute reaction","volume":"67","author":"Vaughan","year":"1967","journal-title":"Ann. Intern. Med."},{"key":"B44","volume-title":"Serum sickness","author":"von Pirqet","year":"1951"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1093\/milmed\/usz357","article-title":"A case of serum sickness-like reaction in an adult treated with omalizumab","volume":"185","author":"Weiss","year":"2020","journal-title":"Mil. Med."},{"key":"B46","volume-title":"Pharmacovigilance: Ensuring the safe use of medicines","year":"2014"},{"key":"B47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000479878","article-title":"Drug-induced pseudoallergy: A review of the causes and mechanisms","volume":"101","author":"Zhang","year":"2018","journal-title":"Pharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.945545\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T06:55:07Z","timestamp":1661842507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.945545\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":47,"alternative-id":["10.3389\/fphar.2022.945545"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.945545","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"945545"}}